Literature DB >> 23879907

Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study.

Matvey Tsivian1, Thomas J Polascik.   

Abstract

OBJECTIVE: To evaluate side-effects, erectile function and capability to preserve adjacent tissues of bilateral focal prostate ablation using low-energy direct current (LEDC) in a canine model.
MATERIALS AND METHODS: In all, 12 male Beagle dogs underwent bilateral focal prostate ablation using the NanoKnife™ LEDC system. Three 19 G monopolar electrodes were transperineally placed on each side of the prostate under transrectal ultrasonographic (TRUS) guidance using a triangular probe array. Intra- and postoperative side-effects were recorded. Erectile function was evaluated at baseline and 4-5 and 26-27 days after ablation. The dogs were killed humanely at 7 (six) and 30 days (six) for gross and microscopic evaluation of the prostate and adjacent organs.
RESULTS: The median (range) prostate volume on TRUS was 12.1 (8.9-17.2) mL. The electrodes were placed at a median distance of 0.55-0.66 cm from the capsule, urethra and rectum. All procedures were completed successfully and recovery was uneventful. There were no episodes of urinary retention. All the dogs were able to achieve erections after ablation. Pathological analyses revealed inflammatory changes in the ablation zone at 7 days and replacement by fibrosis at 30 days. On microscopic examination no histological injury to the capsule, urethra, rectal wall or nervous structures was identified.
CONCLUSIONS: In this study, bilateral focal prostate ablation using LEDC was safe and had a favourable side-effects profile limited to transient minor events. LEDC ablation effectively spared adjacent structures as well as physiological functions in all the dogs.
© 2013 The Authors. BJU International © 2013 BJU International.

Entities:  

Keywords:  ablation; focal therapy; prostate; technology

Mesh:

Year:  2013        PMID: 23879907     DOI: 10.1111/bju.12227

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

1.  Surgery: Good outcomes with low-energy direct current prostate ablation.

Authors:  Mina Razzak
Journal:  Nat Rev Urol       Date:  2013-06-04       Impact factor: 14.432

Review 2.  Image-guided focal therapy for prostate cancer.

Authors:  Sandeep Sankineni; Bradford J Wood; Soroush Rais-Bahrami; Annerleim Walton Diaz; Anthony N Hoang; Peter A Pinto; Peter L Choyke; Barış Türkbey
Journal:  Diagn Interv Radiol       Date:  2014-11       Impact factor: 2.630

3.  Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control.

Authors:  F Ting; M Tran; M Böhm; A Siriwardana; P J Van Leeuwen; A M Haynes; W Delprado; R Shnier; P D Stricker
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-13       Impact factor: 5.554

4.  The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.

Authors:  W van den Bos; D M de Bruin; B G Muller; I M Varkarakis; A A Karagiannis; P J Zondervan; M P Laguna Pes; D P Veelo; C D Savci Heijink; M R W Engelbrecht; H Wijkstra; T M de Reijke; J J M C H de la Rosette
Journal:  BMJ Open       Date:  2014-10-29       Impact factor: 2.692

5.  Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.

Authors:  Matthijs J V Scheltema; Willemien van den Bos; Daniel M de Bruin; Hessel Wijkstra; M Pilar Laguna; Theo M de Reijke; Jean J M C H de la Rosette
Journal:  BMC Cancer       Date:  2016-05-05       Impact factor: 4.430

6.  An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements.

Authors:  Sabrina Campelo; Massimo Valerio; Hashim U Ahmed; Yipeng Hu; Sara L Arena; Robert E Neal; Mark Emberton; Christopher B Arena
Journal:  APL Bioeng       Date:  2017-10-09

7.  A Multicenter Single-Arm Objective Performance Criteria Trial to Determine the Efficacy and Safety of High-Frequency Irreversible Electroporation as Primary Treatment for Localized Prostate Cancer: A Study Protocol.

Authors:  Bi-Ming He; Wei Xue; Wei-Gang Yan; Lei Yin; Bai-Jun Dong; Zhi-En Zhou; Heng-Zhi Lin; Yi Zhou; Yan-Qing Wang; Zhen-Kai Shi; Hai Zhou; Shuai-Dong Wang; Shan-Cheng Ren; Xu Gao; Lin-Hui Wang; Chuan-Liang Xu; Hai-Feng Wang
Journal:  Front Oncol       Date:  2021-11-10       Impact factor: 6.244

8.  A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT).

Authors:  Massimo Valerio; Louise Dickinson; Afia Ali; Navin Ramachandran; Ian Donaldson; Alex Freeman; Hashim U Ahmed; Mark Emberton
Journal:  Contemp Clin Trials       Date:  2014-07-26       Impact factor: 2.226

9.  Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer.

Authors:  M Valerio; P D Stricker; H U Ahmed; L Dickinson; L Ponsky; R Shnier; C Allen; M Emberton
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-09-02       Impact factor: 5.554

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.